Welcome to our dedicated page for IONIS PHARMACEUTICALS SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IONIS PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IONIS PHARMACEUTICALS's regulatory disclosures and financial reporting.
IONS notice of proposed resale of 225,200 shares of Common Stock. The form lists 225,200 shares to be sold pursuant to an option exercise with cash proceeds and identifies Stifel Nicolaus & Company Inc as a broker. The filing also records two prior dispositions by Elizabeth Hougen of 6,988 and 12,922 shares on 01/30/2026 and 01/16/2026, respectively, with their cash amounts.
Ionis Pharmaceuticals executive Patrick R. O'Neil reported an open-market sale of 10,148 shares of common stock at an average price of $75.2525 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025.
Following this sale, O'Neil directly holds 62,211 Ionis shares. The reported sale price reflects a weighted average, with individual trades completed between $74.98 and $75.51 per share.
Ionis Pharmaceuticals Chief Executive Officer Brett P. Monia reported a series of option exercises and stock sales. On March 9–10, 2026, Monia exercised non-qualified stock options covering 148,454 shares of common stock at an exercise price of $60.89 per share.
Across the same two days, Monia sold 160,773 shares of common stock in open-market transactions at weighted average prices in the mid‑$70 range. These sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025. Following the transactions, Monia directly owns 242,662 shares of Ionis Pharmaceuticals common stock.
Ionis Pharmaceuticals EVP Kyle Jenne exercised stock options and sold shares in a planned trade. He exercised options for 37,277 shares of Common Stock at exercise prices of $34.69 and $46.10 per share, then sold 37,277 shares in open-market transactions at weighted average prices of $75.502 and $76.30 per share.
The sales were made under a Rule 10b5-1 trading plan adopted on December 8, 2025. Following these transactions, Jenne directly holds 16,389 shares of Ionis Pharmaceuticals Common Stock.
IONS filed a Form 144 notifying proposed sales of Common Stock. The notice lists two option-exercise related lots of 4,675 and 32,602 shares scheduled on 03/10/2026 to be sold for cash. The filing also reports a prior sale of 1,823 shares on 01/16/2026 for $138,963 by Kyle Jenne.
IONS filing reports proposed sales of Common Stock by Patrick O'Neil. The document lists two transactions: 9,191 shares on 01/06/2026 for $700,602.00 and 6,179 shares on 01/30/2026 for $512,905.00. The filing also references Restricted Stock Units dated 01/15/2018 and an indicated share count of 165,190,000 as of 03/09/2026.
Ionis Pharmaceuticals announced planned changes to its Board of Directors. Long‑serving directors B. Lynne Parshall and Joseph H. Wender will retire at the end of their current terms, with the transitions effective June 4, 2026 and aligned with the 2026 Annual Meeting of Stockholders.
On the same date, Peter N. Reikes will rejoin the board as a director. He recently served as senior strategy advisor with the Advanced Research Projects Agency for Health and earlier as senior advisor to the FDA, following a long career in healthcare investment banking and prior board service at Ionis from 2018 to 2021.
Ionis Pharmaceuticals director Joseph Loscalzo reported option exercises and related share sales in early March. He exercised non-qualified stock options to receive common shares at an exercise price of $38.06 per share, then sold 1,032 common shares at weighted average prices around $80–$81.
The sales, executed on March 3–4, 2026, were carried out under a pre-established Rule 10b5-1 trading plan. After these transactions, Loscalzo directly owned 36,330 common shares of Ionis Pharmaceuticals.
Ionis Pharmaceuticals director Joseph Klein III reported mixed stock transactions involving option exercises and share sales. On March 3, 2026, he exercised non-qualified stock options into 16,000 shares of common stock at exercise prices of $40.05 and $42.88 per share, then sold 21,332 shares in open-market transactions at weighted-average prices between $78.615 and $81.025, pursuant to a Rule 10b5-1 trading plan adopted on November 25, 2025. After these trades, he held 11,014 shares directly and 100 shares were reported as held indirectly by his son, for which he disclaimed beneficial ownership.
IONIS PHARMACEUTICALS INC director Allene M. Diaz reported option exercises and share sales. On March 3, 2026, she exercised non-qualified stock options covering 40,321 shares of common stock at exercise prices of $38.06, $40.05, and $41.08 per share.
On the same date, she sold a total of 54,878 shares of common stock in open-market transactions at weighted average prices ranging from about $78.57 to $81.01, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 25, 2025. Following these transactions, she directly held 3,811 shares of Ionis common stock.